<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2240">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131997</url>
  </required_header>
  <id_info>
    <org_study_id>AD-221P3</org_study_id>
    <nct_id>NCT05131997</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Administrated AD-221 and AD-221A in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A in&#xD;
      patients with primary hypercholesterolemia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>LDL-C change at Week 8</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AD-221</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD-221, Placebo of AD-221A, Placebo of Ezetimibe, and Placebo of Atorvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-221A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo of AD-221, AD-221A, Placebo of Ezetimibe, and Placebo of Atorvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-221B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of AD-221, Placebo of AD-221A, Ezetimibe, and Placebo of Atorvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-221C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of AD-221, Placebo of AD-221A, Placebo of Ezetimibe, and Atorvastatin 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-221</intervention_name>
    <description>PO, Once daily(QD), 8 weeks</description>
    <arm_group_label>AD-221</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-221A</intervention_name>
    <description>PO, Once daily(QD), 8 weeks</description>
    <arm_group_label>AD-221A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-221B</intervention_name>
    <description>PO, Once daily(QD), 8 weeks</description>
    <arm_group_label>AD-221B</arm_group_label>
    <other_name>Ezetimibe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-221C</intervention_name>
    <description>PO, Once daily(QD), 8 weeks</description>
    <arm_group_label>AD-221C</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Subjects with primary hypercholesterolemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with secondary dyslipidemia&#xD;
&#xD;
          -  Other exclusions applied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hak Lee, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong Eun Park</last_name>
    <phone>82-031-891-6989</phone>
    <email>parkje@addpharma.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Hak Lee, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

